Ashwin Kishtagari: How non-selective β-blockers impair hematopoietic regeneration after HCT
Ashwin Kishtagari, Assistant Professor at Vanderbilt-Ingram Cancer Center, shared a post on X about a recent paper by him and colleagues, published in Cancer Discovery:
“I am honored to be a co-first author of our latest publication in Cancer Discovery! This collaboration between Vanderbilt-Ingram Cancer Center and UT Southwestern Medical Center reveals how non-selective β-blockers impair hematopoietic regeneration after HCT.
Our findings highlight the critical role of β-adrenergic signaling in recovery, offering actionable insights to improve outcomes for patients undergoing HCT. Excited to contribute to this impactful work with an incredible team!”
Authors: Jinsuke Nishino, Wenhuo Hu, Ashwin Kishtagari, Stephen Chung, Sean Morrison, et al.
More posts featuring Ashwin Kishtagari.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023